Jazz Pharmaceuticals (JAZZ) Current Deferred Revenue (2010 - 2023)

Jazz Pharmaceuticals' Current Deferred Revenue history runs 14 years deep, the most recent figure standing at $4000.0 for Q3 2023.

• On a quarterly basis, Current Deferred Revenue fell 99.54% year-over-year to $4000.0 in Q3 2023; TTM through Sep 2023 was $4000.0, a 99.54% decrease from a year earlier, with the FY2022 full-year figure at $463000.0, down 81.89% from the prior year.
• Current Deferred Revenue held at $4000.0 in Q3 2023 per JAZZ's latest filing, from $4000.0 in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $11.9 million in Q2 2019 and bottomed at $4000.0 in Q1 2023.
• The 5-year median for Current Deferred Revenue is $3.3 million (2021), against an average of $4.0 million.
• Across the five-year window, Current Deferred Revenue soared 84.96% in 2019 and tumbled 99.76% in 2023, its largest moves.
• Year by year, Current Deferred Revenue stood at $9.6 million in 2019, then slumped by 49.26% to $4.9 million in 2020, then tumbled by 47.42% to $2.6 million in 2021, then slumped by 81.89% to $463000.0 in 2022, then sank by 99.14% to $4000.0 in 2023.
• Per Business Quant, the three latest JAZZ Current Deferred Revenue figures stand at $4000.0 (Q3 2023), $4000.0 (Q2 2023), and $4000.0 (Q1 2023).